ライフサイエンスコーパス: IGF-binding protein

1 s a growth-suppressing factor, as well as an IGF-binding protein.

2 otein-3 (IGFBP-3) belongs to a family of six IGF binding proteins.

3 GF signalling by the increased expression of IGF-binding proteins.

4 by transmembrane receptors and modulated by IGF-binding proteins.

5 een insulin-like growth factor 1 (IGF-I) and IGF binding protein 1 (IGFBP-1) have recently been disco

6 calcium, zinc, and sodium] and serum IGF-I, IGF binding protein 1 (IGFBP-1), IGF binding protein 3 (

7 selected from IGF-1 (n = 9), IGF-2 (n = 1), IGF binding protein 1 (IGFBP1; n = 3), IGFBP3 (n = 3), a

8 trypsin, alpha-fetal protein, ceruloplasmin, IGF binding protein 1, transferrin, apolipoprotein(AI) [

9 [insulin-like growth factor 1], and IGFBP1 [IGF binding protein 1] and IGFBP3]), ILA, and mortality.

10 uble human IGF-I receptor, recombinant human IGF-binding protein 1, and sIGF-II/MPR with similar kine

11 sulin dose, or circulating concentrations of IGF-binding proteins 1 and 3.

12 or the immunoreactivities (ir) of the IGF-I, IGF binding protein-1 (IGFBP-1) and glycogen synthase ki

13 The insulin/IGF binding protein-1 (IGFBP-1) axis is important in coo

14 hat insulin-like growth factor-I (IGF-I) and IGF binding protein-1 (IGFBP-1) could be important deter

15 a), insulinlike growth factor-I (IGF-I), and IGF binding protein-1 (IGFBP-1) in 14 subjects with CF (

16 IGF binding protein-1 (IGFBP-1) is a downstream target o

17 IGF binding protein-1 (IGFBP-1) is a secretory product o

18 y that IGF-I is dependent on the presence of IGF binding protein-1 (IGFBP-1) to act as a wound healin

19 IGF binding protein-1 (IGFBP-1), a hepatocyte-derived se

20 Fasting IGF binding protein-1 concentration was associated with

21 ene under the transcriptional control of the IGF binding protein-1 insulin response element.

22 ns with time were statistically significant (IGF binding protein-1, P-heterogeneity = .0016; sIL6R, P

23 otein-3 levels, and an increase in levels of IGF binding protein-1.

24 free testosterone with increases in SHBG and IGF binding protein-1.

25 oncentrations of insulin-like growth factor (IGF) binding protein-1 (IGFBP1) are associated with insu

26 had higher serum insulin-like growth factor (IGF) binding protein-1 levels (21.0 +/- 8.9 ng/mL versus

27 G6Pase, and a third insulin-regulated gene, IGF-binding protein-1 (IGFBP1); suggests a high degree o

28 hat the hypoxia-inducible factor 1a (HIF-1a)-IGF binding protein 2 (IGFBP2) axis and the tumor-specif

29 The role of IGF binding protein 2 (IGFBP2) in cell growth is intrigu

30 HMGA1 suppresses the abundance of IGF binding protein 2/IGFBP2 and Grb14, inhibitors of IG

31 Insulin-like growth factor (IGF) binding protein 2 (IGFBP2) was discovered and ident

32 tumorigenic cytokine insulin growth factor (IGF) binding protein 2 (IGFBP2).

33 we investigated the levels of GH, IGF-1 and IGF-binding protein 2 (IGFBP-2) after gastric sleeve sur

34 we identified angiopoietin-like proteins and IGF-binding protein 2 (IGFBP2) as new hormones that, tog

35 Addition of either angiopoietin-like 5 or IGF-binding protein 2 to the cultures led to a sizable e

36 Elevated serum levels of IGF-binding protein 2 were observed to correlate with ad

37 IGF binding protein-3 levels, and increased IGF binding protein-2 levels, a pattern suggestive of di

38 was accompanied by a significant increase in IGF binding protein-2 levels, a slight reduction in IGF

39 sion was associated with increased levels of IGF-binding protein-2 (IGFBP-2) in the uterus and ovary,

40 , IGF-I is ultrafiltered in conjunction with IGF-binding protein-2 and is present in proximal tubular

41 Plasma IGF-I and IGF binding protein 3 (IGFBP-3) concentrations and molar

42 Plasma concentrations of IGF-I and IGF binding protein 3 (IGFBP-3) were measured in blood s

43 150-kDa complex including the IGF molecule, IGF binding protein 3 (IGFBP-3), and the acid labile sub

44 erum IGF-I, IGF binding protein 1 (IGFBP-1), IGF binding protein 3 (IGFBP-3), and the IGF-I:IGFBP-3 m

45 F-I) concentrations, frequently adjusted for IGF binding protein 3 (IGFBP-3), have been associated wi

46 Notably, injection of IGF-1 plus IGF binding protein 3 (IGFBP3), but not injection of IGF

47 n assessment using Western blot analysis for IGF binding protein 3 (IGFBP3), IGF-1 receptor (IGF-1R),

48 iously diminished muscle levels of IGF-1 and IGF binding protein 3 both increased following PRT (P <

49 F-I) and the concentration ratio of IGF-I to IGF binding protein 3 were lower in the low-protein, low

50 ternary complex formed by the association of IGF binding protein 3-IGF complexes with a serum protein

51 analyzed for leptin, adiponectin, IGF1, and IGF binding protein 3.

52 bust increase of insulin-like growth factor (IGF) binding protein 3 expression in AR-deficient stroma

53 ed, as were hematocrit (Hct), Ep, IGF-1, and IGF-binding protein 3 (IGF-BP3) levels.

54 ix et al. demonstrate that downregulation of IGF-binding protein 3 (IGFBP-3) and -4, the negative reg

55 led that GR cells exhibited markedly reduced IGF-binding protein 3 (IGFBP-3) and IGFBP-4 RNA.

56 pproximately 13-fold (P < 0.001) increase in IGF-binding protein 3 (IGFBP-3) protein levels were also

57 like growth factor (IGF-I) content and IGF-I:IGF-binding protein 3 (IGFBP-3) ratio as risk factors fo

58 complexes with acid-labile subunit (ALS) and IGF-binding protein 3 (IGFBP-3) to maintain its circulat

59 owth factor I (IGF-I) and/or lower levels of IGF-binding protein 3 (IGFBP-3).

60 een insulin-like growth factor 1 (IGF-1) and IGF-binding protein 3 (IGFBP3) so that the free form of

61 apamil decreases the expression of beta-cell IGF-binding protein 3 (IGFBP3), whereas IGFBP3 is increa

62 at verapamil reduces beta-cell expression of IGF-binding protein 3 (IGFBP3), whereas IGFBP3 was incre

63 ng IGF1 secretion through the suppression of IGF-binding protein 3 expression in prostatic stromal ce

64 1 signaling by ablating IGF-1 and increasing IGF-binding protein 3, increased vSMC apoptosis, and dec

65 to direct expression of rat IGF-I and human IGF binding protein-3 (IGFBP-3) to mammary tissue during

66 thors assessed the associations of IGF-1 and IGF binding protein-3 (IGFBP-3) with cardiovascular dise

67 However, des(1-3)IGF-I, which weakly binds IGF binding protein-3 (IGFBP-3), induced IGF-IR phosphor

68 S of measured serum protein levels of IGF-I, IGF binding protein-3 (IGFBP-3), pregnancy-associated pl

69 proteins insulin-like growth factor (IGF) 1, IGF binding protein-3 and acid-labile subunit, along wit

70 Concomitant administration of IGF binding protein-3 blocked IGF-1-positive inotropic a

71 Suppression of IGF binding protein-3 by palmitate promotes hepatic infl

72 ding protein-2 levels, a slight reduction in IGF binding protein-3 levels, and an increase in levels

73 1% decrease at 1 and 2 wk, respectively) and IGF binding protein-3 levels, and increased IGF binding

74 r risk factors, including circulating IGF-I, IGF binding protein-3, and C-peptide.

75 r insulin, glucose, total IGF-I, free IGF-I, IGF binding protein-3, and estradiol.

76 evels of insulin-like growth factor (IGF)-1, IGF binding protein-3, growth hormone (GH), and somatost

77 rmone, insulin-like growth factor-I (IGF-1), IGF binding protein-3, insulin, cortisol, parathyroid ho

78 cose, insulin, insulin-like growth factor-I, IGF binding protein-3, leptin, or body weight gain.

79 ALS retains the IGF binding protein-3-IGF complexes in the vascular comp

80 IGF-II (Ptrend=0.006 for both) but not with IGF binding protein-3.

81 Similar associations were observed for IGF binding protein-3.

82 n, insulin-like growth factor-I (IGF-I), and IGF binding protein-3.

83 Insulin-like growth factor (IGF) binding protein-3 (IGFBP-3) is known to block IGF a

84 Insulin-like growth factor (IGF) binding protein-3 (IGFBP-3) promotes apoptosis of c

85 Insulin-like growth factor (IGF)-binding protein-3 (IGFBP-3) can stimulate apoptosis

86 ed and validated insulin-like growth factor (IGF)-binding protein-3 (IGFBP3) as a novel miR-21 target

87 This article presents IGF-binding protein-3 (IGFBP-3) as a new modulator of ap

88 IGF-binding protein-3 (IGFBP-3) influences IGF action di

89 IGF-binding protein-3 (IGFBP-3) is a liver-derived, anti

90 IGF-binding protein-3 (IGFBP-3) is the major carrier for

91 Serum IGF-binding protein-3 (IGFBP-3) was significantly lower

92 Subsequently, IGF-1- and IGF-binding protein-3 (IGFBP-3) were analyzed using enzy

93 IGF-binding protein-3 (IGFBP3) is a member of the IGFBP

94 nation of the specificity and sensitivity of IGF-binding protein-3 as an index of nutrition or anabol

95 on into the study and was analyzed for serum IGF-binding protein-3 concentration (by radioimmunoassay

96 IGF-binding protein-3 concentration at the time of admis

97 Variability in IGF-binding protein-3 concentration could not be explain

98 y should be considered when evaluating serum IGF-binding protein-3 concentrations as a marker of nutr

99 F-1 concentrations changed coordinately with IGF-binding protein-3 concentrations in females and male

100 s of the present study were to measure serum IGF-binding protein-3 concentrations in trauma patients

101 y must be considered when interpreting serum IGF-binding protein-3 concentrations in trauma patients.

102 In women, serum IGF-binding protein-3 concentrations were increased with

103 der were not significant predictors of serum IGF-binding protein-3 concentrations when all patients w

104 on insulin-like growth factor-I (IGF-I) and IGF-binding protein-3 gene expression.

105 Importantly, the IGF-binding protein-3, IGFBP-3, is secreted by corneal e

106 cal illness, but there is little research on IGF-binding protein-3, which regulates the bioactivity o

107 eness in vitro through regulated cleavage of IGF-binding protein 4 (IGFBP4).

108 PAPP-A can cleave IGF binding protein-4 (IGFBP-4), upon which IGF-I is lib

109 It was found that IGF binding protein 5 (IGFBP-5), as well as three IGFs e

110 had no effect on apolipoprotein D (ApoD) or IGF binding protein 5 (IGFBP5) expression, but E2/T and

111 n, muscle creatine kinase, beta-enolase, and IGF binding protein 5 and activated the myocyte enhancer

112 H (but not other myofibrillar proteins) and IGF binding protein 5, which may favor cell protein loss

113 parin binding to insulin-like growth factor (IGF)-binding protein 5 (IGFBP-5) leads to a 17-fold decr

114 Overexpression of IGF-binding protein 5 (IGFBP-5) in the human hair xenogr

115 ociated with fibrosis, including Wnt and IGF/IGF-binding protein 5 (IGFBP5).

116 ously shown that insulin-like growth factor (IGF) binding protein- 5 (IGFBP-5) is overexpressed in lu

117 IGF binding protein-5 (BP-5) is an important bone format

118 Therefore, elucidation of the identity of IGF binding protein-5 (BP-5) protease produced by osteob

119 We investigate whether local IGF binding protein-5 (IGFBP-5) promotes the myogenic ac

120 vel of upstream signaling molecules, such as IGF binding protein-5 (IGFBP-5), IGF-1 receptor (IGF-1R)

121 determine whether IGF-I action was altered, IGF binding protein-5, which is synthesized in response

122 Recent studies support the concept that IGF-binding protein-5 (IGFBP-5) stimulates bone formatio

123 sed in MK-PTEN mammary tissue, including the IGF-binding protein-5 (Igfbp5) gene, and others whose ex

124 oped a myogenic cell line that overexpresses IGF-binding protein-5.

125 role of TEC-expressed insulin growth factor (IGF) binding protein-7 (IGFBP7/angiomodulin).

126 e inhibitor metalloproteinase-2 (TIMP-2) and IGF-binding protein-7 (IGFBP7) have been validated for r

127 ical properties such as the interaction with IGF binding proteins and self-aggregation.

128 his IGF-II 'binding-hotspot', revealing that IGF-binding proteins and IGF2R have converged on the sam

129 and acromegaly on locally produced IGF1 and IGF binding proteins are uncertain and in need of furthe

130 BI-31772, which displaces IGF-I from all six IGF-binding proteins at low nanomolar concentrations fro

131 etween common genetic variation in the IGF1, IGF binding protein (BP) 1, and IGFBP3 genes with IGF-I

132 plasma levels of insulin-like growth factor (IGF) binding protein (BP)-2 or IGFBP-3 would predict can

133 on of insulin-like growth factor (IGF)-I and IGF-binding protein (BP) 3 with cancer and cardiovascula

134 fically cleaving insulin-like growth factor (IGF) binding proteins, causing increased IGF bioavailabi

135 and tissues is controlled by members of the IGF binding protein family (IGFBP).

136 s (A6-A11, A7-B7, and A20-B19) maintained by IGF-binding proteins; IGF-swap has alternative pairing (

137 uded demonstrating the effectiveness of IGF1/IGF binding protein (IGF1/IGFBP) complex dissociation us

138 levels of IGF-I with concomitant lowering of IGF binding protein (IGFBP)-3 are associated with increa

139 Serum concentrations of IGF-I, IGF binding protein (IGFBP)-3, and their molar ratio (IG

140 Levels of IGF-1, IGF-2, IGF binding proteins (IGFBP) 1-3, and IL-6 were measured

141 isoform of IGF-1 with decreased affinity for IGF binding proteins (IGFBP) due to a 3-amino acid delet

142 ) IGF-1, which has a much lower affinity for IGF binding proteins (IGFBP) than IGF-1.

143 Since IGF-1 action is influenced by IGF binding proteins (IGFBP), this study was conducted t

144 he expression of insulin-like growth factor (IGF)-binding protein (IGFBP)-1, a secreted protein that

145 Insulin-like growth factor (IGF)-binding protein (IGFBP)-6 decreases cancer cell pro

146 kDa consisting of one molecule each of IGF, IGF-binding protein (IGFBP) 3, and an acid labile subuni

147 Investigating IGF-binding protein (IGFBP) modulation of IGF-II actions

148 ired for expression of genes encoding IGF-2, IGF-binding protein (IGFBP)-2 and IGFBP-3.

149 ) complexed with its natural binding protein IGF-binding protein (IGFBP)-3 (rhIGF-I/IGFBP-3) is a nov

150 muscle, while recent evidence suggests that IGF-binding protein (IGFBP)-3 acts as an insulin antagon

151 th and increases lymphocyte numbers and that IGF-binding protein (IGFBP)-3 has an opposing effect, in

152 In this study, the endogenous expression of IGF-binding protein (IGFBP)-3 was examined in human reti

153 nsulin-like growth factor (IGF)-1 as well as IGF-binding protein (IGFBP)-3.

154 tor I (IGF-I) knockout mice demonstrate that IGF-binding protein (IGFBP)-5, an important bone formati

155 e is still little information about IGFs and IGF-binding proteins (IGFBP) in cancers detected by the

156 questered into binary complexes with several IGF-binding proteins (IGFBP-2, IGFBP-3, and IGFBP-5).

157 reatment of cells with either alphaIR3 or an IGF-binding protein, IGFBP-3, led to a 75% inhibition of

158 atients further revealed elevated IGF-II and IGF binding proteins IGFBP4 and IGFBP6.

159 ong induction of insulin-like growth factor (IGF)-binding protein IGFBP5, an antagonist of IGF signal

160 rowth, the specific contributions of the six IGF binding proteins (IGFBPs 1-6) to these processes are

161 els of insulin-like growth factor 1 (IGF-1), IGF binding proteins (IGFBPs) 1 and 3, insulin, osteocal

162 IGF binding proteins (IGFBPs) modify IGF-I actions indep

163 Because IGF binding proteins (IGFBPs) play a critical role in mo

164 The IGF binding proteins (IGFBPs) represent a class of natur

165 IGFs are bound to IGF binding proteins (IGFBPs), which modulate IGF ligand

166 eptors and modulated by a family of secreted IGF binding proteins (IGFBPs).

167 iate IGF bioavailability through cleavage of IGF binding proteins (IGFBPs).

168 activity is regulated tightly by a family of IGF binding proteins (IGFBPs).

169 studies to be important for association with IGF binding proteins (IGFBPs).

170 The insulin-like growth factor (IGF) binding proteins (IGFBPs) modulate the actions of t

171 However, an unrelated class of proteins, the IGF-binding proteins (IGFBPs) also bind IGF-1 in the ser

172 on bone, and alterations in the IGFs and/or IGF-binding proteins (IGFBPs) could be responsible for t

173 Given that several secreted IGF-binding proteins (IGFBPs) exist in mammals, our work

174 le of insulin-like growth factor (IGF)-I and IGF-binding proteins (IGFBPs) in the regulation of vascu

175 between IGF-1/2, the IGF-1 receptor, and the IGF-binding proteins (IGFBPs) leads to elevated IGF-1 se

176 Specific IGF-binding proteins (IGFBPs) modulate the interaction o

177 of insulin-like growth factor I (IGF-I) and IGF-binding proteins (IGFBPs) occur in children with end

178 metabolism yet control of their activity by IGF-binding proteins (IGFBPs) remains controversial.

179 The ability of IGF-binding proteins (IGFBPs) such as IGFBP-3 to reduce

180 mainly by the liver and circulates bound to IGF-binding proteins (IGFBPs), either as binary complexe

181 Thus, inhibitors of IGF-binding proteins (IGFBPs), especially IGFBP-3, could

182 ce of insulin-like growth factors (IGFs) and IGF-binding proteins (IGFBPs), which promoted or inhibit

183 F) signaling through proteolytic cleavage of IGF-binding proteins (IGFBPs).

184 bolism, with their availability regulated by IGF-binding proteins (IGFBPs).

185 , distinctive for the pivotal roles of local IGF-binding proteins (IGFBPs).

186 of high affinity, specific binding proteins (IGF-binding proteins; IGFBPs) that are present in the in

187 get genes 4E-BP and l (2)efl and the insulin/IGF-binding protein IMP-L2.

188 An excess of one or more of the six IGF binding proteins in the 35-kD serum fractions result

189 e present study, we examined the predominant IGF-binding protein in the CSF, IGFBP2.

190 59, 60, Ala31)hIGF-I] with high affinity to IGF-binding proteins (Ki = 0.3-3.9 nM) and no biological

191 Neither IGF-1 analogues with low affinity to IGF binding proteins nor proteinase inhibitors obliterat

192 nding protein 4 (IGFBP-4), the most abundant IGF-binding protein produced by rodent smooth muscle cel

193 IGF-I, rescued from structural ambiguity by IGF-binding proteins, reflects fine-tuning of signal tra

194 re medium (R0), and to avoid interference by IGF-binding proteins, secreted IGF peptides were isolate

195 ound mostly to a family of six high affinity IGF-binding proteins, which form stable complexes with I